Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer.
Antigens, CD
/ biosynthesis
Antigens, CD20
/ biosynthesis
Antigens, Differentiation, T-Lymphocyte
/ biosynthesis
B-Lymphocytes
/ metabolism
Base Sequence
Cell Line, Tumor
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Immunoglobulin D
/ biosynthesis
Immunoglobulin G
/ immunology
Immunohistochemistry
Lectins, C-Type
/ biosynthesis
Lymphocytes
/ cytology
Models, Statistical
Phenotype
Prognosis
RNA-Seq
Receptors, Antigen, B-Cell
/ metabolism
Single-Cell Analysis
Transcriptome
Triple Negative Breast Neoplasms
/ immunology
Tumor Necrosis Factor Receptor Superfamily, Member 7
/ biosynthesis
Tumor Necrosis Factor-alpha
/ biosynthesis
User-Computer Interface
Journal
Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R
Informations de publication
Date de publication:
15 08 2021
15 08 2021
Historique:
received:
19
11
2020
revised:
23
03
2021
accepted:
14
06
2021
pubmed:
6
7
2021
medline:
8
1
2022
entrez:
5
7
2021
Statut:
ppublish
Résumé
In breast cancer, humoral immune responses may contribute to clinical outcomes, especially in more immunogenic subtypes. Here, we investigated B lymphocyte subsets, immunoglobulin expression, and clonal features in breast tumors, focusing on aggressive triple-negative breast cancers (TNBC). In samples from patients with TNBC and healthy volunteers, circulating and tumor-infiltrating B lymphocytes (TIL-B) were evaluated. CD20
Identifiants
pubmed: 34224371
pii: 0008-5472.CAN-20-3773
doi: 10.1158/0008-5472.CAN-20-3773
pmc: PMC7611538
mid: EMS127844
doi:
Substances chimiques
Antigens, CD
0
Antigens, CD20
0
Antigens, Differentiation, T-Lymphocyte
0
CD69 antigen
0
Immunoglobulin D
0
Immunoglobulin G
0
Lectins, C-Type
0
Receptors, Antigen, B-Cell
0
Tumor Necrosis Factor Receptor Superfamily, Member 7
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4290-4304Subventions
Organisme : Medical Research Council
ID : MC_PC_19041
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A11527
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L023091/1
Pays : United Kingdom
Organisme : Breast Cancer Now
ID : BREAST CANCER NOW KCL RESEARCH UNIT
Pays : United Kingdom
Organisme : British Heart Foundation
ID : NH/12/2/29427
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/H018409/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L01257X/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L01257X/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A15774
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A11060
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A22788
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600097
Pays : United Kingdom
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
Cancer Res. 2012 Mar 1;72(5):1070-80
pubmed: 22266112
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8
pubmed: 18503082
PLoS One. 2012;7(2):e32639
pubmed: 22393427
J Biol Chem. 2008 Feb 1;283(5):2654-62
pubmed: 18048365
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Nat Med. 2016 Nov;22(11):1303-1313
pubmed: 27775704
Nat Protoc. 2020 Apr;15(4):1484-1506
pubmed: 32103204
Front Immunol. 2016 Sep 27;7:388
pubmed: 27729912
Int J Epidemiol. 2017 Aug 1;46(4):1103-1103i
pubmed: 28158674
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Nucleic Acids Res. 2012 Sep 1;40(17):e134
pubmed: 22641856
Breast Cancer Res Treat. 2020 Apr;180(2):369-377
pubmed: 32034580
Haematologica. 2001 Sep;86(9):995-6
pubmed: 11532633
BMC Biotechnol. 2007 Oct 18;7:70
pubmed: 17945015
Cell. 2019 Nov 14;179(5):1191-1206.e21
pubmed: 31730857
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Mod Pathol. 2017 Sep;30(9):1204-1212
pubmed: 28621322
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
Trends Immunol. 2014 Nov;35(11):571-80
pubmed: 25443495
J Immunol. 2000 Feb 15;164(4):1829-38
pubmed: 10657631
Nat Genet. 2019 Mar;51(3):560-567
pubmed: 30742113
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nat Commun. 2019 Jul 16;10(1):3120
pubmed: 31311926
Lancet Oncol. 2020 Jan;21(1):44-59
pubmed: 31786121
Front Immunol. 2018 Nov 20;9:2660
pubmed: 30515157
Cancer Immunol Immunother. 2011 Dec;60(12):1729-38
pubmed: 21779876
Nucleic Acids Res. 2018 Jul 2;46(W1):W264-W270
pubmed: 29668996
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Methods Mol Biol. 2015;1343:199-218
pubmed: 26420719
Cancer Res Treat. 2017 Apr;49(2):399-407
pubmed: 27488875
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Curr Opin Immunol. 2008 Jun;20(3):332-8
pubmed: 18417336
Br J Cancer. 2013 Sep 17;109(6):1676-84
pubmed: 23982600
JCI Insight. 2019 Aug 13;5:
pubmed: 31408436
Arthritis Res Ther. 2018 Jun 7;20(1):114
pubmed: 29880013
Am Soc Clin Oncol Educ Book. 2015;:e31-9
pubmed: 25993190
PLoS One. 2018 Jul 5;13(7):e0199034
pubmed: 29975708
Clin Cancer Res. 2018 Oct 15;24(20):5098-5111
pubmed: 30068707
J Clin Invest. 2010 Apr;120(4):1111-24
pubmed: 20234093
Clin Cancer Res. 2009 Jul 1;15(13):4277-87
pubmed: 19549767
Cell. 2018 Sep 6;174(6):1373-1387.e19
pubmed: 30193111
Cancer Immunol Immunother. 2014 Jul;63(7):643-62
pubmed: 24695950
Gut. 2017 Feb;66(2):342-351
pubmed: 26669617
Nat Rev Cancer. 2012 Mar 22;12(4):278-87
pubmed: 22437872
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
J Exp Med. 2002 Jul 1;196(1):65-75
pubmed: 12093871